Cargando…

Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis

Here we present a comprehensive mass cytometry analysis of peripheral innate lymphoid cell (ILC) subsets in relapsing/remitting MS (RRMS) patients prior to and after onset of cladribine tablets (CladT). ILC analysis was conducted on CyTOF data from peripheral blood mononuclear cells (PBMC) of MS pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aglas-Leitner, F. T., Juillard, P., Juillard, A., Byrne, S. N., Hawke, S., Grau, G. E., Marsh-Wakefield, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701791/ https://www.ncbi.nlm.nih.gov/pubmed/36437270 http://dx.doi.org/10.1038/s41598-022-24617-4

Ejemplares similares

Circulating CCR6 (+) ILC proportions are lower in multiple sclerosis patients
por: Aglas‐Leitner, Florentina, et al.
Publicado: (2022)

Oral Cladribine Impairs Intermediate, but Not Conventional, Monocyte Transmigration in Multiple Sclerosis Patients across a Model Blood-Brain Barrier
por: Lin, Linda Y., et al.
Publicado: (2023)

Cladribine Reduces Trans-Endothelial Migration of Memory T Cells across an In Vitro Blood–Brain Barrier
por: Ford, Rachel K., et al.
Publicado: (2022)

Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients
por: Nguyen, Kristy, et al.
Publicado: (2022)

Peripheral B‐cell dysregulation is associated with relapse after long‐term quiescence in patients with multiple sclerosis
por: Marsh‐Wakefield, Felix, et al.
Publicado: (2022)

IgG(3) (+) B cells are associated with the development of multiple sclerosis
por: Marsh‐Wakefield, Felix, et al.
Publicado: (2020)

Mass cytometry reveals innate lymphoid cell differentiation pathways in the human fetal intestine
por: Li, Na, et al.
Publicado: (2018)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis
por: Sadeghi Hassanabadi, Negar, et al.
Publicado: (2022)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020)

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

T Cell Contamination in Flow Cytometry Gating Approaches for Analysis of Innate Lymphoid Cells
por: Burkhard, Sara H., et al.
Publicado: (2014)

Analysis and purification of innate lymphoid cells in human intestine and blood by flow cytometry
por: Qi, Jingjing, et al.
Publicado: (2023)

Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis
por: Alshamrani, Foziah, et al.
Publicado: (2020)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2019)

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update
por: Jack, Dominic, et al.
Publicado: (2021)

Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
por: Clavelou, Pierre, et al.
Publicado: (2023)

Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis
por: Rakers, Florian, et al.
Publicado: (2023)

Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
por: Molnarfi, Nicolas, et al.
Publicado: (2012)

Performance of spectral flow cytometry and mass cytometry for the study of innate myeloid cell populations
por: van der Pan, Kyra, et al.
Publicado: (2023)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Murphy, Julie A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7045daj0dhmhfihhe1po267i3u